- Home
- NUVL vs ELAN Comparison
NUVL vs ELAN Comparison
Compare NUVL & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ELAN
- Stock Information
- Founded
- NUVL 2017
- ELAN 1954
- Country
- NUVL United States
- ELAN United States
- Employees
- NUVL N/A
- ELAN N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ELAN Biotechnology: Pharmaceutical Preparations
- Sector
- NUVL Health Care
- ELAN Health Care
- Exchange
- NUVL Nasdaq
- ELAN Nasdaq
- Market Cap
- NUVL 5.5B
- ELAN 5.4B
- IPO Year
- NUVL 2021
- ELAN 2018
- Fundamental
- Price
- NUVL $79.49
- ELAN $11.01
- Analyst Decision
- NUVL Strong Buy
- ELAN Buy
- Analyst Count
- NUVL 11
- ELAN 7
- Target Price
- NUVL $112.36
- ELAN $16.29
- AVG Volume (30 Days)
- NUVL 420.4K
- ELAN 5.0M
- Earning Date
- NUVL 03-04-2025
- ELAN 02-25-2025
- Dividend Yield
- NUVL N/A
- ELAN N/A
- EPS Growth
- NUVL N/A
- ELAN N/A
- EPS
- NUVL N/A
- ELAN 0.41
- Revenue
- NUVL N/A
- ELAN $4,454,000,000.00
- Revenue This Year
- NUVL N/A
- ELAN $2.20
- Revenue Next Year
- NUVL N/A
- ELAN $2.48
- P/E Ratio
- NUVL N/A
- ELAN $26.71
- Revenue Growth
- NUVL N/A
- ELAN 1.99
- 52 Week Low
- NUVL $61.80
- ELAN $10.77
- 52 Week High
- NUVL $113.51
- ELAN $18.80
- Technical
- Relative Strength Index (RSI)
- NUVL 43.83
- ELAN 35.16
- Support Level
- NUVL $77.84
- ELAN $10.77
- Resistance Level
- NUVL $85.21
- ELAN $11.77
- Average True Range (ATR)
- NUVL 3.78
- ELAN 0.41
- MACD
- NUVL -0.46
- ELAN -0.06
- Stochastic Oscillator
- NUVL 12.08
- ELAN 17.14
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.